We have previously shown that mice immunized with solid-matrix-antibody-antigen (SMAA) complexes in the absence of adjuvants show vigorous humoral and cell-mediated immune responses to the immunizing antigen. Here we report that various proteins involved in inducing protective immune responses to different viruses can easily and simply be incorporated into SMAA complexes and that such complexes act as powerful multivalent immunogens. Construction of such SMAA complexes may be one of the most practical and effective ways of producing multivalent subunit vaccines for use in humans and animals.
There are numerous advantages in developing subunit vaccines based on proteins capable of eliciting protective immune responses. However, a number of major problems need to be overcome before such vaccines can be successfully produced. The antigens involved in inducing protective immunity need to be identified, a good source of these antigens is required, and then procedures need to be developed to purify the antigens. In addition, immunization schemes need to be devised for presenting the antigens to the immune system in such a way as to induce protective immunity. To produce successful vaccines to some viruses, it may be necessary to induce both virus-neutralizing antibody and specific T-cell responses, and since the major target antigens for B and T cells may reside on different virus proteins, multiple virus antigens may need to be incorporated into such vaccines. Furthermore, since the major target antigens for T cells may be different from individual to individual, depending on major histocompatibility complex status (1, 3, 5, 7), different proteins from the same virus may need to be incorporated into the vaccine to ensure appropriate immune responses in all individuals of a heterozygous population. Also, since vaccines tend to protect against disease rather than infection, it may be beneficial to induce a broad immune response, thereby ensuring a rapid secondary immune response upon subsequent infection with a virulent virus. Thus, for example, induction of a broad T-helper cell response may be advantageous, particularly since it has been demonstrated that T-helper cells which recognize antigenic determinants on internal virus proteins may help B-cell responses to surface proteins present on the same virus particle through the mechanism of B-cell antigen presentation (8, 15, 17) . Besides these arguments for multivalent vaccines, it would, if possible, be both economically desirable and practically convenient to incorporate into subunit vaccines the appropriate proteins from a variety of infectious agents. In our study of immunity to paramyxoviruses, we have been developing an immunization scheme which may permit the development of such multivalent subunit vaccines (11, 12) . The basis of the immunization scheme is to attach monoclonal antibodies to particulate solid matrices; the solid-matrix-antibody complexes are then used to purify the proteins of interest (ideally in such a way as to saturate the antibody with the antigen), and the resulting solid-matrix-* Corresponding author.
antibody-antigen (SMAA) complexes are used as immunogens. We have shown that immunization of mice with such SMAA complexes in the absence of adjuvants results in induction of vigorous humoral and cell-mediated immune responses (11) .
Here we report that SMAA complexes can be very easily constructed to produce multivalent immunogens containing various virus glycoproteins known to be involved in inducing protective immunity from a number of different viruses. The protein A-immunoglobulin Fc-binding sites on fixed and killed suspensions of Staphylococcus aureus Cowan strain A (6) were saturated with a mixture of protein A-binding monoclonal antibodies (in approximately equimolar ratios) specific for glycoprotein D of herpes simplex virus (HSV) (LP14; 9), the HA proteins of influenza virus (HC245) and measles virus (B10; 16), and the HN proteins of simian virus 5 (SV5) (SV5-HN-4a; 13) and parainfluenza virus type 2 (PIV2) (PIV2-HN-3a; 14). The unbound antibody was removed by suspension and sedimentation (2,500 x g for 3 min) of these complexes three times in phosphate-buffered saline. These strain A-antibody complexes were used to purify the respective proteins from lysates of virus (measles virus, HSV, PIV2, and SV5)-infected tissue culture cells and from detergent extracts of purified influenza virus. Soluble antigen extracts were made from SV5-, PIV2-, or HSVinfected BHK cells and from measles virus-infected Vero cells as previously described (13) . A detergent extract was also made from purified influenza virus by incubating the virus with extraction buffer (20 mM Tris hydrochloride [pH 7.2], 5 mM EDTA, 0.5% Nonidet P-40, 0.1% sodium dodecyl sulfate, 0.65 M NaCl) for 30 min at +4°C. The particulate material was then removed by centrifugation at 100,000 x g for 30 min. These extracts were then mixed together before being incubated with the solid-matrix-antibody complexes (20 [l of a 10% [wt/vol] suspension of solid-matrix-antibody complexes per 2 x 108 cell equivalents of each antigen extract or -1 mg of influenza virus extract) for 4 to 6 h at +4°C. The resulting SMAA complexes were washed three times by sedimentation from (3,300 x g for 3 to 10 min) and resuspension in extraction buffer and washed twice in phosphate-buffered saline. Estimations of the amounts of virus proteins in SMAA complexes were made by sodium dodecyl sulfate-polyacrylamide electrophoretic analysis of the complexes as previously described (11) . Groups of three mice were immunized twice intraperitoneally without adjuvants Antigen-antibody complexes have been previously used as immunogens for the preparation of antisera of defined specificity and to enhance immune responses to specific proteins in experimental animals (4, 10, 18 (11, 12) .
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for the ability to precipitate virus proteins from infected tissue culture cells (Fig. 1) . The sera from mice immunized with such complexes precipitated only the appropriate virus proteins. These sera were also tested for the ability either to neutralize virus infectivity (HSV, measles virus, PIV2, and SV5; 14) or to react with purified influenza virus attached to sheets of nitrocellulose (-100 ,ug of purified virus per sheet [7 by 5 cm]) in a radioimmunoassay (11) . These results showed that sera from immunized mice had high titers of antibodies to all of these viruses ( Table 1) . 
